Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Blood. 2014 Jun 12;
Authors: Yeh CH, Gross PL, Weitz JI
The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin for treatment of the majority of patients with venous thromboembolism (VTE). With a rapid onset of action and the capacity to be administered in fixed doses without routine coagulation monitoring, NOACs streamline VTE treatment. In phase III trials in patients with acute symptomatic VTE, NOACs have been shown to be non-inferior to conventional anticoagulant therapy for prevention of recurrence and are associated with less bleeding. Rivaroxaban and dabigatran are already licensed for VTE treatment in the United States, and apixaban and edoxaban are under regulatory consideration for this indication. As the number of approved drugs increases, clinicians will need to choose the right anticoagulant for the right VTE patient. To help with this decision, this review (a) compares the pharmacological profiles of the NOACs, (b) outlines the unique design features of the phase III trials that evaluated the NOACs for VTE treatment, (c) reviews the results of these trials highlighting similarities and differences in the findings, (d) provides perspective as to which VTE patients should receive conventional treatment and which are candidates for NOACs, and (e) offers suggestions as to how to choose amongst the NOACs.
PMID: 24923298 [PubMed - as supplied by publisher]